VIRIVirios Therapeutics, Inc.

Nasdaq virios.com


$ 0.23 $ -0.01 (-3.75 %)    

Friday, 05-Jul-2024 15:13:12 EDT
QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ 0.2311
$ 0.25
$ 0.00 x 0
$ 0.00 x 0
$ 0.23 - $ 0.25
$ 0.16 - $ 2.42
487,408
na
4.45M
$ 1.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-01-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-18-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-23-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 maxim-group-initiates-coverage-on-virios-therapeutics-with-buy-rating-announces-price-target-of-1

Maxim Group analyst Jason McCarthy initiates coverage on Virios Therapeutics (NASDAQ:VIRI) with a Buy rating and announces P...

 virios-therapeutics-inc-to-offer-85m-shares-of-common-stock-at-020-per-share

- SEC Filing

 reported-earlier-virios-therapeutics-prices-17m-public-offering-of-85m-common-stock-to-commence-preparations-for-planned-imc-2-long-covid-phase-2b-study-at-020share

Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechno...

 virios-therapeutics-announces-21m-proposed-public-offering-of-common-stock

Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechno...

 virios-therapeutics-q1-2024-gaap-eps-007-misses-004-estimate

Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of...

 virios-therapeutics-announces-publication-of-international-patent-for-imc-2-covering-antiviral-treatment-of-long-covid

- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally –- Active Long-COVID c...